Hagerty is a monopolistic, highly profitable tollbooth on the multi-billion-dollar collector car ecosystem with compounding structural growth, though investors must vigilantly monitor underwriting volatility as the firm transitions to retaining 100% of its insurance risk.
dLocal's profitable, fast-growing emerging-market payments platform trades at a depressed free cash flow multiple, but take-rate compression and large founder divestitures remain headwinds.
LivaNova is a deeply entrenched medical device compounder perfectly positioned to harvest explosive margin expansion from recent Medicare reimbursement hikes, though investors must tolerate near-term execution risk surrounding its critical supply chain scale-up and sleep apnea regulatory filings.
Excelerate has masterfully transformed into an integrated, cash-printing global LNG utility trading at a deeply misunderstood growth multiple, though investors must stomach the inherent geopolitical volatility of its emerging-market sovereign counterparties.
Nelnet is an exceptional capital-compounding machine disguised as a boring student loan servicer, using massive cash flows from an amortizing legacy portfolio to fund highly profitable tech and banking ventures at a deep discount to its true sum-of-the-parts intrinsic value.
WillScot is an impenetrable, cash-printing infrastructure monopoly trading at a deeply misunderstood discount due to optical margin compression from massive new project wins, though investors must monitor its elevated debt leverage against the backdrop of fluctuating non-residential construction cycles.
Sphere Entertainment is the undisputed, highly scalable monopoly of ultra-immersive live entertainment, poised for massive margin expansion via a capital-light global franchise model, though investors must tolerate the structural drag of its legacy regional sports networks.
ESAB is executing a masterful, high-margin transformation into an industrial software and inspection powerhouse, trading at a deeply misunderstood discount, though investors must tolerate near-term balance sheet leverage as the company digests its massive acquisition.
Ascendis Pharma's TransCon technology platform is rapidly scaling a highly profitable rare disease portfolio led by Yorvipath and Yuviwel, though investors must monitor ongoing BioMarin patent litigation and reliance on a single drug delivery mechanism.
Credicorp is the highly profitable, monopolistic tollbooth of Peruvian finance, successfully scaling its Yape fintech ecosystem to lock in decades of structural growth, though investors must remain hyper-vigilant regarding provisioning spikes tied to unpreventable macro and climate shocks.
Amdocs is an impenetrable, highly cash-generative tollbooth for global telecom operations trading at a deeply distressed valuation, though investors must accept stagnant top-line growth tied to constrained carrier capital expenditures.
Enact Holdings operates as a highly disciplined, cash-generating fortress within the U.S. mortgage insurance oligopoly, relentlessly compounding per-share value through aggressive buybacks and flawless credit risk transfer, though investors face the overhang of Genworth's majority ownership.